Table 2 The chemical properties and pharmacological activities of novel compounds
From: Pharmacological activities and mechanisms of action of Pogostemon cablin Benth: a review
| Compound name | Formula | Plant part | Analytical method | Type of compound | Bioactivity | References |
|---|---|---|---|---|---|---|
| Cablinosides A | C23H34O10 | Leaves | HR-ESI-MS; UV; IR; NMR; HPLC; CD | Glycosides | α-glucosidase inhibitory activity (IC50 = 278.4 ± 2.8 µM) | [35] |
| Cablinosides B | C23H34O10 | Leaves | HR-ESI-MS; UV; IR; NMR; HPLC; CD | Glycosides | [35] | |
|
14-nor-β-patchoul- 1(5)-ene-2,4-dione | C14H18O2 | Leaves/Stems | TLC; NMR; IR; HR-ESI-MS | Sesquiterpenoids | – | [36] |
|
2β-Methoxy-14-nor-β-patchoul-1(5)- ene-4-one | C15H22O2 | Leaves/Stems | TLC; NMR; IR; HR-ESI-MS | Sesquiterpenoids | – | [36] |
|
14-nor-β-patchoul- 1(5),2-diene-4-one | C14H18O | Leaves/Stems | TLC; NMR; IR; HR-ESI-MS | Sesquiterpenoids | Cytotoxic activities against NCIH1975 (IC50 = 49.9 µM) | [36] |
| Cytotoxic activities against HePG-2 (IC50 = 56.0 µM) | ||||||
| 14-nor-β-Patchoul-1(5)-ene-4-one | C14H20O | Leaves/Stems | TLC; NMR; IR; HR-ESI-MS | Sesquiterpenoids | – | [36] |
| Pocahemiketals A | C15H20O4 | Aerial parts | HR-ESI-MS; IR; NMR; X-ray; ECD | Sesquiterpenoids | – | [37] |
| Pocahemiketals B | C14H20O3 | Aerial parts | HR-ESI-MS; IR; NMR; X-ray; ECD | Sesquiterpenoids | Vasorelaxant activity (EC50 = 16.32 µM) | [37] |
| Patchouliguaiol A | C15H24O2 | Aerial parts | HR-ESI-MS; IR; NMR; ECD; X-ray | Sesquiterpenoids | – | [38] |
| Patchouliguaiol B | C15H26O2 | Aerial parts | HR-ESI-MS; IR; NMR; ECD; X-ray | Sesquiterpenoids | Neuroprotective effect (50µM) | [38] |
| Patchouliguaiol C | C15H24O2 | Aerial parts | HR-ESI-MS; IR; NMR; ECD; X-ray | Sesquiterpenoids | Vasorelaxant activity against PHE-induced contraction (EC50 = 5.4 µM) | [38] |
| Antifungal activity against Candida albicans (MIC = 500 µM) | ||||||
| Patchouliguaiol D | C15H22O | Aerial parts | HR-ESI-MS; IR; NMR; ECD; X-ray | Sesquiterpenoids | – | [38] |
| Patchouliguaiol E | C15H20O | Aerial parts | HR-ESI-MS; IR; NMR; ECD; X-ray | Sesquiterpenoids | – | [38] |
| Patchouliguaiol F | C15H24O2 | Aerial parts | HR-ESI-MS; IR; NMR; ECD; X-ray | Sesquiterpenoids | Vasorelaxant activity against PHE- induced contraction (EC50 = 1.6 µM) | [38] |
| Vasorelaxant activity against KCl- induced contraction (EC50 = 24.2 µM) | ||||||
| Antifungal activity against Candida albicans (MIC = 300 µM) | ||||||
| Patchouliguaiol G | C15H24O2 | Aerial parts | HR-ESI-MS; IR; NMR; ECD; X-ray | Sesquiterpenoids | Neuroprotective effect (50µM) | [38] |
| 7-epi-chabrolidione A | C15H24O2 | Aerial parts | NMR | Seco-guaianes | Neuroprotective effect (50µM) | [38] |
| 1,7-di-epi-chabrolidione A | C15H24O2 | Aerial parts | NMR | Seco-guaianes | Neuroprotective effect (50µM) | [38] |